Somatosensory Phenotyping of ADPKD

NCT ID: NCT06970028

Last Updated: 2025-11-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-09-09

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Over 60% of patients with ADPKD suffer from pain, mostly in the abdomen, flank and back, often leading to the diagnosis. It is challenging to manage and cure the pain; approximately 39% of patients are not satisfied with their pain treatment, since the pain prevents them from doing various activities, affecting their quality of life. Pain can be present before enlargement of the kidneys, the source of the pain is often unknown and common analgesics are insufficient to manage the pain or cannot be taken due to renal impairment. By further investigating and characterizing the pain phenotype of the ADPKD population, pain management might be improved and alternative therapeutic approaches might be developed. In this clinical study, pain will be assessed in patients with ADPKD using Quantitative Sensory Testing (QST) on the dominant hand and the lower back, together with four questionnaires regarding pain and quality of life. These results will be compared with the somatosensory profile of matched healthy volunteers.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

ADPKD Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with ADPKD

Patients with ADPKD will be included (≥ 12 years old). The somatosensory profile will be described using Quantitative Sensory Testing and questionnaires regarding pain and quality of life.

Quantitative Sensory Testing

Intervention Type OTHER

We will perform QST on the dominant hand and lower back.

Questionnaires regarding pain and quality of life

Intervention Type OTHER

Questionnaires will be filled out by patients with ADPKD to evaluate pain and quality of life.

Healthy volunteers

Healthy volunteers will be included (≥ 12 years old), matched with the patient group based on age, sex and BMI. The somatosensory profile will be described using Quantitative Sensory Testing and the BPI-SF questionnaire.

Quantitative Sensory Testing

Intervention Type OTHER

We will perform QST on the dominant hand and lower back.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Quantitative Sensory Testing

We will perform QST on the dominant hand and lower back.

Intervention Type OTHER

Questionnaires regarding pain and quality of life

Questionnaires will be filled out by patients with ADPKD to evaluate pain and quality of life.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients with ADPKD

* Subject is ≥ 12 years old.
* Subject is diagnosed with ADPKD.

Healthy volunteers

* Subject is ≥ 12 years old.
* Subject is in good general health, based on medical history and vital signs.
* Subject is matched to the patient group for age, sex and BMI.

Exclusion Criteria

Patients with ADPKD

* Subject has eczema, scleroderma, psoriasis, dermatitis, or any other abnormality on the skin of the dominant hand and/or lower back which, in the investigator's opinion, might interfere with the study assessments.
* Subject is currently undergoing dialysis, had a kidney transplant or is a user of tolvaptan.
* Female who is pregnant or breastfeeding.
* Simultaneous participation in another study which, in the investigator's opinion, might confound the results of the study.
* Subject is unable to refrain from drinking alcohol 24 hours prior to each study visit, and/or consumes ≥ 3 alcoholic consumptions per day.
* Subject is a regular user of cannabis, any illicit drugs and/or has a history of drug abuse.
* Subject is unable to refrain from drinking caffeinated beverages (such as coffee, tea, cola,…) 24 hours prior to each study visit.
* Subject has used concomitant drugs and/or treatments in a period smaller than or equal to 5 half-lives prior to enrollment, that may interfere, in the investigator's opinion, with the study results.
* Subject has a history of any illness or condition which, in the investigator's opinion, may interfere with safe and optimal participation in the study.

Healthy volunteers

* Subject has a history of any illness or condition which may affect the normal somatosensory functionality.
* Subject has eczema, scleroderma, psoriasis, dermatitis, or any other abnormality on the skin of the dominant hand and/or lower back which, in the investigator's opinion, might interfere with the study assessments.
* Female who is pregnant or breast-feeding.
* Simultaneous participation in another study which, in the investigator's opinion, might confound the results of the study.
* Subject is unable to refrain from drinking alcohol 24 hours prior to each study visit, and/or consumes ≥ 3 alcoholic consumptions per day.
* Subject is a regular user of cannabis, any illicit drugs and/or has a history of drug abuse.
* Subject is unable to refrain from drinking caffeinated beverages (such as coffee, tea, cola,…) 24 hours prior to each study visit.
* Subject has used concomitant drugs and/or treatments in a period smaller than or equal to 5 half-lives prior to enrollment, that may interfere, in the investigator's opinion, with the study results.
* Subject has a history of any illness or condition which, in the investigator's opinion, may interfere with safe and optimal participation in the study.
Minimum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Universitaire Ziekenhuizen KU Leuven

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jan de Hoon, MD, PhD, MSc

Role: PRINCIPAL_INVESTIGATOR

UZ Leuven

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UZ Leuven

Leuven, , Belgium

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Flore Van Olmen, MSc

Role: CONTACT

+32 016 34 22 01

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Flore Van Olmen, MSc

Role: primary

+32 016 34 22 01

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

S70540

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

The CPH-MBD Cohort
NCT07193056 NOT_YET_RECRUITING
Handgrip Exercise Training and CKD
NCT07094906 RECRUITING NA
ADPKD Cohort Study
NCT02084849 COMPLETED